Skip to main content

Table 3 Clinical and radiological study outcomes

From: Treatment satisfaction, adherence and behavioral assessment in patients de – escalating from natalizumab to interferon beta

 

IFN B 1B

NTZ

p-value

 

(n = 9)

(n = 10)

 

Number of relapses, median (range)^

3

0

0.447

- month 1 to 6

2

0 (0)

 

- month 6 to 12

1

0 (0)

 

Proportion of relapse free patients over the follow up period (number)°

78% (7)

100% (10)

0.206

Annualized relapse rate

   

- during run-in period NTZ

0 (0)

0 (0–1.3)

0.497

EDSS

   

- at month 6

3.0 (1.5-3.5)

3.0 (1.5-3.5)

0.966

- at month 12

3.5 (1.5-3.5)

3.0 (1.5-3.5)

0.315

Number of new T2 lesions, median (range) ^

   

- at month 6

1.5 (0–9)

0 (0–2)

0.043

- at month 12

0 (0–12)

0 (0)

0.234

Number of Gd enhancing lesions, median (range) ^

   

- at month 6

0 (0–5)

0 (0)

0.442

- at month 12

0 (0–2)

0 (0–1)

0.694

  1. ^U-Mann Whitney test; °two-sided exact Fisher test.